OncoZenge AB (publ) (FRA:8LY)

Germany flag Germany · Delayed Price · Currency is EUR
0.577
-0.023 (-3.83%)
At close: Dec 5, 2025
52.85%
Market Cap 6.96M
Revenue (ttm) 251.72K
Net Income (ttm) -773.81K
Shares Out n/a
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.577
Previous Close 0.600
Day's Range 0.577 - 0.577
52-Week Range 0.272 - 0.668
Beta n/a
RSI 61.74
Earnings Date Feb 18, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Pharmaceutical Preparations
Founded 2020
Employees 1
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8LY
Full Company Profile

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.